Evidence map›Paper›PMID 24335964›Full record

ArticleCancers2013

Circulating Tumor Cell Detection and Capture by Photoacoustic Flow Cytometry in Vivo and ex Vivo.

Ekaterina I Galanzha, Vladimir P Zharov

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06488365 (In Vivo Liquid Biopsy for Early Detection of Metastatic Melanoma), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06488365 narecruitingnot on this mapstarted 2025, after this paper: background citation

In Vivo Liquid Biopsy for Early Detection of Metastatic Melanoma

TypeinterventionalSponsorCytoastraRan2025 to 2026Enrolled180ConditionsMelanoma, Circulating Tumor Cells, Metastatic Melanoma, DiagnosisArmsCytophone
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Biogenic Imaging Contrast Agents.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  12. The sound of blood: photoacoustic imaging in blood analysis.Medicine in novel technology and devices · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ekaterina I Galanzha
Vladimir P ZharovPhillips Classic Laser and Nanomedicine Laboratories, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA. zharovvladimirp@uams.edu.
University of Arkansas for Medical Sciences · US

Funding

In vivo real-time detection of circulating melanoma cellsR01CA131164 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI SUEN, JAMES · 2009 to 2019
$3.1M
Multifunctional nanotubes for in vivo detecting/purging circulating cancer cellsR01EB009230 · NIBIB · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAROV, VLADIMIR P · 2009 to 2012
$1.2M
NCI NIH HHS R01 CA131164NIBIB NIH HHS R01 EB009230
6 · The paper itself

Abstract

Despite progress in detecting circulating tumor cells (CTCs), existing assays still have low sensitivity (1-10 CTC/mL) due to the small volume of blood samples (5-10 mL). Consequently, they can miss up to 103-104 CTCs, resulting in the development of barely treatable metastasis. Here we analyze a new concept of in vivo CTC detection with enhanced sensitivity (up to 102-103 times) by the examination of the entire blood volume in vivo (5 L in adults). We focus on in vivo photoacoustic (PA) flow cytometry (PAFC) of CTCs using label-free or targeted detection, photoswitchable nanoparticles with ultrasharp PA resonances, magnetic trapping with fiber-magnetic-PA probes, optical clearance, real-time spectral identification, nonlinear signal amplification, and the integration with PAFC in vitro. We demonstrate PAFC's capability to detect rare leukemia, squamous carcinoma, melanoma, and bulk and stem breast CTCs and its clusters in preclinical animal models in blood, lymph, bone, and cerebrospinal fluid, as well as the release of CTCs from primary tumors triggered by palpation, biopsy or surgery, increasing the risk of metastasis. CTC lifetime as a balance between intravasation and extravasation rates was in the range of 0.5-4 h depending on a CTC metastatic potential. We introduced theranostics of CTCs as an integration of nanobubble-enhanced PA diagnosis, photothermal therapy, and feedback through CTC counting. In vivo data were verified with in vitro PAFC demonstrating a higher sensitivity (1 CTC/40 mL) and throughput (up to 10 mL/min) than conventional assays. Further developments include detection of circulating cancer-associated microparticles, and super-rsesolution PAFC beyond the diffraction and spectral limits.

Identifiers

PMID24335964
PMCPMC3875961
OpenAlexW2080310376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.